Related Experiment Video
Updated: Mar 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
ATRIAL FIBRILLATION AND STROKE PREVENTION PRACTICES IN PATIENTS WITH CANDIDACY FOR ANTICOAGULATION THERAPY
Insights
Many atrial fibrillation patients at high risk for stroke are not receiving adequate anticoagulant therapy. This study highlights a gap in stroke prevention practices for these individuals.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial Fibrillation (AF) increases stroke risk due to left atrial thrombi.
- Antithrombotic therapy, primarily Vitamin K antagonists (VKAs), is recommended for AF patients.
- This study assessed stroke prevention in local AF patients eligible for anticoagulation.
Purpose of the Study:
- To evaluate current stroke prevention strategies in patients with Atrial Fibrillation.
- To identify the prevalence of appropriate anticoagulation use in high-risk AF patients.
- To determine adherence to stroke prevention guidelines in a local population.
Main Methods:
- A descriptive cross-sectional study was conducted in Peshawar, Pakistan.
- Included patients with EKG-confirmed AF and a CHA2DS2-VASc score ≥ 2 or mitral stenosis.
- Excluded patients with other indications for anticoagulation.
Main Results:
- 205 AF patients were studied; 72.7% were candidates for anticoagulation.
- Only 27.5% received adequate anticoagulant therapy (VKAs or novel oral anticoagulants).
- Most patients received dual antiplatelet therapy (DAPT) instead of anticoagulation.
Conclusions:
- A significant proportion of high-risk AF patients are undertreated for stroke prevention.
- Current stroke prevention practices for AF patients in this region are suboptimal.
- There is a critical need to improve the initiation and management of antithrombotic therapy in AF.
Background:
Stroke secondary to Atrial Fibrillation is usually due to thrombi formed in the left atrium and left atrial appendage embolizing to cause ischemic stroke. Therefore, in patients with Atrial Fibrillation, antithrombotic therapy is recommended to prevent stroke. Vitamin K antagonist therapy is most widely used antithrombotic therapy for patients with valvular and non valvular AF. Aspirin is recommended only in low risk patients. This study was conducted to determine the stroke prevention practices in local patients with atrial fibrillation who were candidates for anticoagulation therapy.
Methods:
This was descriptive cross sectional study conducted at Cardiovascular Department Lady Reading Hospital Peshawar and Cardiology Department Hayatabad Medical Complex Peshawar. Sampling technique was non probability consecutive. Patients visiting OPD of respective hospitals with EKG evidence of AF and having CHADES VASC score 2 or more or having mitral stenosis and AF were included in the study. Patients with additional indications for anticoagulation were excluded from the study.
Results:
A total of 205 patients with atrial fibrillation were studied. Mean age was 60.7±14.7 years. Male were 55.6% (n=114) while 44.4% (n=91) were female. Of these 149 (72.7%) were candidates for anticoagulation based on CHA2DS2 VASc score of 2 and more or mitral stenosis with AF. Only 27.5% (n=41) patients were adequately treated with anticoagulant therapy using VKA or novel oral anticoagulant drugs. Majority of them were getting dual antiplatelet therapy (DAPT).
Conclusion:
Most patients with AF and high risk characteristics for thromboembolism are not receiving proper stroke prevention therapies.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Dysrhythmias VI: Management of Dysrhythmias
Venous Thrombosis IV: Nursing Management
Atherosclerosis IV: Nursing Management

